Melatonin affects the immobility time of rats in the forced swim test: the role of serotonin neurotransmission

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Vincenzo MicaleF Drago

Abstract

The efficacy of melatonin or its derivatives in depressive patients has been recently considered for clinical application. However, the evidence for its effect on experimental models of depression is not consolidated. Here, the effects of melatonin on the model of forced swim test (FST) paradigm were studied in male rats of the Wistar strain after acute intraperitoneal (i.p.) administration of 0.1, 0.5 or 1 mg/kg of the hormone. Melatonin at doses of 0.5 and 1 mg/kg, but not of 0.1 mg/kg, decreased the immobility of rats in the FST paradigm suggesting a possible antidepressant-like activity. The dose of 0.5 mg/kg appeared to be as potent as clomipramine 50 mg/kg in reducing the immobility time of rats in the FST paradigm. The effect of melatonin on immobility time of rats in the FST paradigm was abolished by the simultaneous injection of the non-selective melatonin antagonist, luzindole (0.25 mg/kg, subcutaneously). Similarly, administration of small quantities of serotonin (5-HT, 5 ng/1 microl) or of the 5-HT(2A)/5-HT(2C) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (2 ng/1 microl) injected into the amygdale totally suppressed the reduction of immobility time in the FST paradigm induced by melatonin 0.5 mg/kg...Continue Reading

References

Dec 1, 1992·Psychiatry Research·H D'haenenL Kaufman
Mar 1, 1989·Naunyn-Schmiedeberg's Archives of Pharmacology·K O Aley, S K Kulkarni
Jan 1, 1984·Psychopharmacology·P Willner
Mar 1, 1994·British Journal of Pharmacology·G A KennettT P Blackburn
Jun 24, 1993·European Journal of Pharmacology·D A GolombekD P Cardinali
Feb 1, 1996·General and Comparative Endocrinology·J B Zawilska, J Z Nowak
Jan 1, 1996·Neuroscience and Biobehavioral Reviews·D A GolombekD P Cardinali
Apr 1, 1997·Neuropharmacology·G A KennettT P Blackburn
Dec 31, 1997·The Journal of Clinical Psychiatry·R M Pinder
Mar 21, 1998·Neuroreport·D H OverstreetB Guardiola-Lemaitre
Jul 22, 1998·European Journal of Pharmacology·A ArgyriouA Philippu
Jun 22, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·F DragoG Lo Menzo
Mar 26, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mariusz PappElisabeth Mocaër
Nov 1, 1964·Journal of Pharmaceutical Sciences·N WATZMANW J KINNARD
Sep 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Matthew N HillBoris B Gorzalka
Dec 4, 2004·Behavioural Pharmacology·E TatarczyńskaE Chojnacka-Wójcik

❮ Previous
Next ❯

Citations

Dec 18, 2009·European Archives of Psychiatry and Clinical Neuroscience·Shadab Ataur RahmanColin Michael Shapiro
Aug 15, 2013·Cell and Tissue Research·Vincenzo MicaleAlexandra Sulcova
Jun 29, 2010·Acta Pharmacologica Sinica·Shao-wen TianHai-feng Deng
Jan 26, 2013·Pharmacology & Therapeutics·Laurence LanfumeyMichel Hamon
Oct 31, 2015·Annual Review of Pharmacology and Toxicology·Jiabei LiuMargarita L Dubocovich
Jun 12, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alessandra TamburellaFilippo Drago
Apr 22, 2010·European Journal of Pharmacology·Ricardo W BinfaréAna Lúcia S Rodrigues
Mar 3, 2009·European Journal of Pharmacology·Bernardo C DetanicoElaine Elisabetsky
Jul 8, 2008·European Journal of Pharmacology·Yusuf ErgünMehmet Fatih Karaaslan
Jan 29, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Vincenzo MicaleFilippo Drago
Jul 13, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Malcolm Lader
Sep 1, 2015·Brain Research Bulletin·Jana TchekalarovaRichard Teke Ngomba
Sep 24, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Inmaculada TassetIsaac Túnez
Jul 3, 2013·Physiology & Behavior·Seenu HaridasKailash Manda
Jun 15, 2012·The International Journal of Neuropsychopharmacology·Alessandra TamburellaSalvatore Salomone
Jul 18, 2008·The International Journal of Neuropsychopharmacology·Tal AshkenazyNoga Kronfeld-Schor
Nov 11, 2016·Oxidative Medicine and Cellular Longevity·Josiel Mileno MackRui Daniel Prediger
Jul 7, 2011·Journal of Psychopharmacology·Sergio Domínguez-LópezGabriella Gobbi
Mar 8, 2018·British Journal of Pharmacology·Marcela Valdés-TovarGloria Benítez-King
Nov 8, 2018·The European Journal of Neuroscience·Kyle D KetchesinColleen A McClung
Aug 8, 2018·International Journal of Molecular Sciences·Rosa Estrada-ReyesGloria Benítez-King

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.